Next, it was observed that CRC tumors in which MLH1 dysfunction is present (either hereditary or sporadic) in a fraction of tumors (approximately 30% of MSI-H sporadic CRCs or 5% of all sporadic CRCs) lead to subsequent MSH3 mutation and inactivation. This evidence concerns the gene MLH1 and colorectal carcinoma.